Kurs & Likviditet
-16,70%
|
60,8 MNOK
Kursutveckling och likviditet under dagen för detta pressmeddelande
Kalender
2024-11-13 | Kvartalsrapport 2024-Q3 |
2024-08-07 | Kvartalsrapport 2024-Q2 |
2024-05-24 | Ordinarie utdelning PHO 0.00 NOK |
2024-05-23 | Årsstämma 2024 |
2024-05-15 | Kvartalsrapport 2024-Q1 |
2024-02-21 | Bokslutskommuniké 2023 |
2023-11-08 | Kvartalsrapport 2023-Q3 |
2023-08-09 | Kvartalsrapport 2023-Q2 |
2023-05-10 | Kvartalsrapport 2023-Q1 |
2023-05-04 | Ordinarie utdelning PHO 0.00 NOK |
2023-05-03 | Årsstämma 2023 |
2023-02-24 | Bokslutskommuniké 2022 |
2023-02-23 | Bokslutskommuniké 2022 |
2022-11-02 | Kvartalsrapport 2022-Q3 |
2022-08-10 | Kvartalsrapport 2022-Q2 |
2022-05-11 | Kvartalsrapport 2022-Q1 |
2022-04-29 | Ordinarie utdelning PHO 0.00 NOK |
2022-04-28 | Årsstämma 2022 |
2022-02-23 | Bokslutskommuniké 2021 |
2021-11-17 | Kvartalsrapport 2021-Q3 |
2021-08-11 | Kvartalsrapport 2021-Q2 |
2021-07-28 | Extra Bolagsstämma 2021 |
2021-05-21 | Ordinarie utdelning PHO 0.00 NOK |
2021-05-20 | Årsstämma 2021 |
2021-05-19 | Kvartalsrapport 2021-Q1 |
2021-03-03 | Bokslutskommuniké 2020 |
2020-11-10 | Kvartalsrapport 2020-Q3 |
2020-08-18 | Kvartalsrapport 2020-Q2 |
2020-06-11 | Ordinarie utdelning PHO 0.00 NOK |
2020-06-10 | Årsstämma 2020 |
2020-05-07 | Kvartalsrapport 2020-Q1 |
2020-02-27 | Bokslutskommuniké 2019 |
2019-11-07 | Kvartalsrapport 2019-Q3 |
2019-08-07 | Kvartalsrapport 2019-Q2 |
2019-06-19 | Extra Bolagsstämma 2019 |
2019-05-14 | Kvartalsrapport 2019-Q1 |
2019-05-10 | Ordinarie utdelning PHO 0.00 NOK |
2019-05-09 | Årsstämma 2019 |
2019-02-27 | Bokslutskommuniké 2018 |
2018-11-08 | Kvartalsrapport 2018-Q3 |
2018-08-08 | Kvartalsrapport 2018-Q2 |
2018-05-23 | Kvartalsrapport 2018-Q1 |
2018-05-11 | Ordinarie utdelning PHO 0.00 NOK |
2018-05-09 | Årsstämma 2018 |
2018-02-27 | Bokslutskommuniké 2017 |
2017-11-08 | Kvartalsrapport 2017-Q3 |
2017-08-23 | Kvartalsrapport 2017-Q2 |
2017-05-23 | Kvartalsrapport 2017-Q1 |
2017-04-28 | Ordinarie utdelning PHO 0.00 NOK |
2017-04-27 | Årsstämma 2017 |
2017-02-15 | Bokslutskommuniké 2016 |
2016-11-15 | Kvartalsrapport 2016-Q3 |
2016-08-23 | Kvartalsrapport 2016-Q2 |
2016-05-10 | Kvartalsrapport 2016-Q1 |
2016-04-29 | Ordinarie utdelning PHO 0.00 NOK |
2016-04-28 | Årsstämma 2016 |
2016-02-11 | Bokslutskommuniké 2015 |
2015-10-29 | Kvartalsrapport 2015-Q3 |
2015-08-13 | Kvartalsrapport 2015-Q2 |
2015-05-06 | Kvartalsrapport 2015-Q1 |
2015-05-02 | Ordinarie utdelning PHO 0.00 NOK |
2015-04-30 | Årsstämma 2015 |
2015-02-12 | Bokslutskommuniké 2014 |
2014-11-06 | Kvartalsrapport 2014-Q3 |
2014-08-26 | Kvartalsrapport 2014-Q2 |
2014-05-28 | Ordinarie utdelning PHO 0.00 NOK |
2014-05-27 | Årsstämma 2014 |
2014-05-07 | Kvartalsrapport 2014-Q1 |
2014-02-27 | Bokslutskommuniké 2013 |
2013-10-23 | Kvartalsrapport 2013-Q3 |
2013-08-22 | Kvartalsrapport 2013-Q2 |
2013-05-23 | Ordinarie utdelning |
2013-05-22 | Årsstämma 2013 |
2013-04-25 | Kvartalsrapport 2013-Q1 |
2013-02-28 | Bokslutskommuniké 2012 |
2012-10-26 | Kvartalsrapport 2012-Q3 |
2012-08-24 | Kvartalsrapport 2012-Q2 |
2012-05-10 | Årsstämma 2012 |
2012-04-26 | Kvartalsrapport 2012-Q1 |
2012-02-16 | Bokslutskommuniké 2011 |
2011-10-26 | Kvartalsrapport 2011-Q3 |
2011-08-18 | Kvartalsrapport 2011-Q2 |
2011-04-27 | Kvartalsrapport 2011-Q1 |
2011-04-27 | Årsstämma 2011 |
2011-02-17 | Bokslutskommuniké 2010 |
2010-10-27 | Kvartalsrapport 2010-Q3 |
2010-08-19 | Kvartalsrapport 2010-Q2 |
2010-04-28 | Kvartalsrapport 2010-Q1 |
2010-02-19 | Bokslutskommuniké 2009 |
2009-11-26 | Bonusutdelning |
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Medicinteknik |
2023-02-23 08:00:16
Oslo, Norway, 23 February 2023 Photocure ASA (OSE:PHO) today reported
Hexvix[®]/Cysview[®] revenues of NOK 94.9 million in the fourth quarter of 2022
(Q4 2021: NOK 94.2 million), and an EBITDA of minus NOK 16.9 million (NOK -5.5
million). The total revenues increased 10% to NOK 104.2 million and there were
57 blue light towers placed in the quarter, a record high for expanding the
installed base of blue light cystoscopes. Photocure expects to deliver new
SaphiraT blue light tower installations in the range of 65 to 75, consolidated
product revenue growth above 20%, and positive EBITDA (ex-business development
spending) in 2023.
"The fourth quarter of 2022 was highlighted by a record number of Saphira tower
installations in the U.S., demonstrating ongoing high demand for blue light
capital equipment and serving as a leading indicator of the growth opportunity
ahead for Hexvix/Cysview. The fourth quarter also had its challenges as did the
full year of 2022, including a multi-quarter delay in the launch of Saphira,
healthcare worker staffing shortages which pressured urology procedure volumes,
and hospital budget tightening as staffing shortages exacerbated broader
inflationary pressures," says Dan Schneider, President & Chief Executive
Officer of Photocure.
Photocure reported total group revenues of NOK 104.2 million in the fourth
quarter of 2022 (NOK 94.5 million), and an EBITDA* of minus NOK 16.9 million
(NOK -5.5 million). The Hexvix/Cysview revenues ended at NOK 94.9 million in the
quarter (Q4 2021: NOK 94.2 million). The EBIT was NOK -23.1 million (NOK -11.5
million) and the cash balance at the end of the third quarter 2022 was NOK 268.1
million.
"I am proud of our commercial team's ability to facilitate the placement of the
highest number of towers ever recorded by Photocure in a single quarter, 57
installations of BLC towers. The logistics of placing this many systems in one
quarter, with most new account installations occurring toward the end of Q4,
required our commercial team to commit the majority of their time and focus on
customer relations and training. Even with the unprecedented number of new
Saphira and flexible BLC installations in the fourth quarter, the demand for
blue light capital equipment remains strong," Schneider adds.
During the quarter, 31 new blue light towers were installed